{"organizations": [], "uuid": "a1e365b78dc7ae1859932400c580d58839527f1e", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-bristol-myers-says-opdivo-to-demon/brief-bristol-myers-says-opdivo-to-demonstrate-superior-survival-benefit-compared-with-chemotherapy-in-a-predominantly-chinese-population-with-previously-treated-non-small-cell-lung-cancer-idUSFWN1RQ0XC", "country": "US", "domain_rank": 408, "title": "BRIEF-Bristol-Myers Says Opdivo To Demonstrate Superior Survival Benefit Compared With Chemotherapy In A Predominantly Chinese Population With Previously Treated Non Small Cell Lung Cancer", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-13T23:45:00.000+03:00", "replies_count": 0, "uuid": "a1e365b78dc7ae1859932400c580d58839527f1e"}, "author": "", "url": "https://www.reuters.com/article/brief-bristol-myers-says-opdivo-to-demon/brief-bristol-myers-says-opdivo-to-demonstrate-superior-survival-benefit-compared-with-chemotherapy-in-a-predominantly-chinese-population-with-previously-treated-non-small-cell-lung-cancer-idUSFWN1RQ0XC", "ord_in_thread": 0, "title": "BRIEF-Bristol-Myers Says Opdivo To Demonstrate Superior Survival Benefit Compared With Chemotherapy In A Predominantly Chinese Population With Previously Treated Non Small Cell Lung Cancer", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "opdivo to demonstrate superior survival benefit", "sentiment": "neutral"}, {"name": "nsclc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "bristol-myers squibb co", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Market News April 13, 2018 / 8:46 PM / Updated 5 minutes ago BRIEF-Bristol-Myers Says Opdivo To Demonstrate Superior Survival Benefit Compared With Chemotherapy In A Predominantly Chinese Population With Previously Treated Non Small Cell Lung Cancer Reuters Staff 1 Min Read \nApril 13 (Reuters) - Bristol-Myers Squibb Co: \n* OPDIVO (NIVOLUMAB), FIRST PD-1 INHIBITOR TO DEMONSTRATE SUPERIOR SURVIVAL BENEFIT COMPARED WITH CHEMOTHERAPY IN A PREDOMINANTLY CHINESE POPULATION WITH PREVIOUSLY TREATED NON -SMALL CELL LUNG CANCER (NSCLC) \n* IN PHASE 3 CHECKMATE-078 TRIAL, OPDIVO REDUCED RISK OF DEATH BY 32% VERSUS CHEMOTHERAPY \n* IN STUDY, OPDIVO DEMONSTRATED A STATISTICALLY SIGNIFICANT BENEFIT VERSUS DOCETAXEL ON PRIMARY ENDPOINT OF OVERALL SURVIVAL \n* IN TRIAL, TWO SECONDARY ENDPOINTS OF ORR, MEDIAN DURATION OF RESPONSE DEMONSTRATED DURABILITY WITH OPDIVO VERSUS DOCETAXEL Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-04-13T23:45:00.000+03:00", "crawled": "2018-04-13T23:56:01.001+03:00", "highlightTitle": ""}